Document:

EX-10.24

 Exhibit 10.24 

LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (this “Agreement”) is made as of
May 22, 2007 (the “Effective Date”), between KHH BIOSCI, INC., a North Carolina corporation, having its principal office at 634 Lake Hogan Lane, North Carolina 27516 United
States of America (“KHH”) and MARRONE ORGANIC INNOVATIONS, INC., a Delaware corporation, having its principal office at 215 Madson Place, Suite B, Davis, California
95618, United States of America (“MOI”). 
 ARTICLE 1 

BACKGROUND 

1.1    KHH has conducted research on the extract of Reynoutria sachalinensis and formulations that include
this extract and owns a license and various intellectual property rights associated with such extract. KHH is interested in sub-licensing such rights to MOI for further commercial development and marketing. 

1.2    MOI is in the business of research, development, registration and commercialization of natural products as
biopesticides. MOI is interested in assessing the above described on such extract and related rights of KHH, which MOI may develop, register and bring to market. 

1.3    To advance these goals, MOI and KHH have determined to enter into a commercial relationship regarding the
future development, registration, commercialization, sales and marketing of products based on such extract and related rights. 
 ARTICLE
2 
 DEFINITIONS 

2.1    “Affiliate” means, in relation to a party to this Agreement, a body corporate which from
time to time is, directly or indirectly, controlled by, in control of, or under common control with, such party and, for these purposes, “control” shall consist of the ownership of over 50% of the voting stock of the applicable entity.

 2.2    “Agro-Kanesho Assignment and License Agreement” means that Assignment and License Agreement
between KHH and Agro-Kanesho Co., Ltd., a Japanese corporation dated 18 September 2000, attached as Exhibit A. 

2.3    “BASF” means BASF Aktiengesellschaft. 

2.4    “BASF Agreement” means the Assignment and License Agreement between KHH and BASF, executed
April 20, 1998. 
 2.5    “BASF Technology Rights” means the technology rights, including
TECHNICAL INFORMATION, as set forth in the BASF Agreement. Attached as Exhibit B. 
 2.6    “BASF
Territory” means the Territory as defined in the BASF Agreement. 

 2.7    “Confidential Information” means, as to either
party and without limitation, such party’s proprietary or confidential data, know-how, formulas, compositions, processes, documents, designs, sketches, photographs, plans, graphs, drawings, specifications, equipment, samples, reports, findings,
inventions, ideas and information, including business information related to Products and the BASF Technology Rights and the KHH Technology Rights. 

2.8    “Customer” means any purchaser of a Product other than KHH, MOI, an Affiliate or a
Sublicensee. 
 2.9    “Deductible Expenses” means the following items of expense incurred in
connection with Sales of Products to the extent paid or allowed by MOI or a Sublicensee, and included in accordance with recognized principles of accounting in the gross sales price billed: (a) sales, use or turnover taxes; (b) excise,
value added, importation or other taxes, custom duties or consular fees; (c) transportation, freight, and handling charges, and insurance on shipments to customers; (d) trade, cash or quantity discounts or rebates to the extent actually
granted (including government-mandated rebates); (e) rebates, refunds, and credits for any rejected or returned Products or due to billing errors or because of retroactive price reductions, rebates or chargebacks; (f) uncollected accounts
receivable attributable to Sales of Products; and (g) sales related fees or commissions paid for efforts in arranging actual Sales of Products. 

2.10    “Exclusive” means that for the term of this Agreement KHH will not use or license to any
licensee, other than MOI, the Licensed Patents, the BASF Technology Rights, the Technology Rights, subject to the rights of BASF to “Technical Information” (as defined in the BASF Agreement) under Section 3.3 of the BASF Agreement,
and subject to the Agro-Kanesho Assignment and License Agreement. 
 2.11    “Licensed Patents”
means: (i) all domestic and foreign patents and patent applications listed in Exhibit C attached hereto; (iii) all divisionals, continuations, and continuations-in-part of such patents and patent applications; (iv) all patents
that issue on any of the foregoing patent applications; (v) all foreign counterparts of the foregoing patents and patent applications; and (vi) all reissues, reexaminations, renewals, extensions, and supplementary protection certificates
relating to any of the foregoing patents. Exhibit C may be updated from time to time on mutual agreement. 

2.12    “Licensed Patent Rights” means any and all rights under the Licensed Patents. 

2.13    “Net Revenues” means the amount received by MOI or a Sublicensee, in each case for the
Sale of a Product to a Customer, less the Deductible Expenses applicable to such Sale. Net revenues shall also include imputed Net Revenues as provided in Section 10.4. 

2.14    “Product” means any product or device that is covered by, or is made by or utilizes a
process or material covered by, any Valid Claim or which utilizes any BASF Technology Rights or KHH Technology Rights. 

2.15    “Registration” means approval by the United States Environmental Protection Agency of a
microbial, a substance or a mixture of substances, as a biochemical or microbial pesticide. 

 2.16    “Sale” means the sale, transfer, exchange or
other commercial disposition of a Product. In case of doubt, Sales of Products will be deemed consummated no later than receipt of payment by a Customer for the applicable transaction involving such Product. 

2.17    “Sublicensee” will mean, with respect to a particular Product, a third party to which MOI has
granted a license or sublicense under any or all of the Licensed Patent Rights. 
 2.18    “KHH Technology
Rights” means any and all ideas, inventions, formulae, processes, trade secrets and substantial know-how, intellectual property, techniques, methods, specifications, practices, data and other forms of information relating to the processes,
methods and techniques for manufacturing, formulating and using the Licensed Patent Rights or relating to the Products, whether patentable or not and whether or not reduced to practice, including Licensed Patent Rights and registration data in each
case owned or licensable by KHH or directly or indirectly derived from the foregoing or from Confidential Information of Licensor at any time during the term of this Agreement, other than BASF Technology Rights. 

2.19    “Technology Rights” means KHH Technology Rights and BASF Technology Rights. 

2.20    “Territory” means: 

a) with respect to the Licensed Patents, the United States of America 

b) with respect to the BASF Technology Rights, the BASF Territory 

c) with respect to the KHH Technology Rights, the world. 

2.21    “Trademark” means all right of KHH to the trademark Milsana® as well as any unregistered version thereof, and associated goodwill. 

2.22    “Valid Claim” means, with respect to any country, a claim of an issued patent within the Licensed
Patents that has not, with respect to such country (a) expired or been canceled, (b) been declared invalid by an unreversed decision of a court or other appropriate body of competent jurisdiction from which there can be no further appeal,
(c) been admitted to be invalid or unenforceable through reexamination, reissue, disclaimer or otherwise, and/or (d) been abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement. 

ARTICLE 3 

REPRESENTATIONS, WARRANTIES AND COVENANTS OF KHH 

KHH hereby represents, warrants and covenants to MOI as follows: 

3.1    Corporate Power and Authority.  KHH has the corporate power and authority to execute and
deliver this Agreement and perform its obligations hereunder. KHH also represents and warrants that, except as set forth in Exhibit C, it has the right and the authority, including ownership or appropriate and valid licenses, to grant the licenses
set forth in Article 5 and to grant and perform its other rights and obligations hereunder. 

 3.2    Compliance with Law. KHH will conduct its activities and
operations in material compliance with all applicable laws, statutes, rules or regulations. 
 3.3    No
Conflicting Agreement.  KHH represents and warrants that it has not granted to any third party any right or interest in any of the Licensed Patent Rights or other Technology Rights that is inconsistent with the rights granted to MOI
herein and will not grant any third party such a right during the term of this Agreement. 
 3.4    No
Litigation.  KHH represents and warrants that, as of the date of execution of this Agreement, there are no pending or, to its actual knowledge, threatened actions, suits, investigations, claims, or proceedings in any way relating to
the Licensed Patent Rights or other Technology Rights. 
 3.5    BASF Agreement.  KHH represents
and warrants that this Agreement is consistent with the relevant terms of the BASF Agreement and that MOI has no direct obligation to BASF under the BASF Agreement. As between KHH and MOI, KHH is solely responsible for performing its obligations
under the BASF Agreement. 
 ARTICLE 4 

REPRESENTATIONS, WARRANTIES AND COVENANTS OF MOI 

MOI represents, warrants and covenants the following to KHH: 

4.1 Corporate Power and Authority.  MOI has the corporate power and authority to execute and deliver this Agreement
and perform its obligations hereunder and thereunder. 
 4.2 Compliance with Law.  MOI will conduct its activities
and operations in material compliance with all applicable laws, statutes, rules or regulations. 
 ARTICLE 5 

LICENSE GRANT AND APPLICATION ASSIGNMENT 

5.1    Grant.  Subject to the terms and conditions of this Agreement, to the terms and conditions
of the BASF Agreement, to the terms and conditions of the Agro-Kanesho Assignment and License Agreement. KHH hereby grants to MOI an Exclusive, royalty-bearing, sublicensable license under the Licensed Patent Rights, BASF Technology Rights and KHH
Technology Rights; and Trademarks, to research, develop, make, have made, import, have imported, use, have used, sell, have sold, offer for sale, have offered for sale, and otherwise exploit Products in the Territory. 

5.2    Limits on Sublicensing.  MOI has the right to grant nonexclusive or exclusive sublicenses
hereunder, provided, that: (a) MOI will include all Net Revenues of Sublicensees in MOI’s reports to KHH, as provided in Section 7.1, and MOI will pay royalties thereon to KHH calculated pursuant to
Section 6.2; and (b) MOI may grant sublicenses of no greater scope than the licenses granted under Section 5.1. 

5.3    Assignment of Sublicenses.  Any sublicenses granted by MOI of the rights it receives
under Section 5.1, including any nonexclusive sublicenses, will remain in effect and, at 

 
MOI’s and KHH’s election, may be assigned to KHH if the license in Section 5.1 terminates pursuant to Article 13, provided the financial obligations of each
Sublicensee to KHH will be at least the same as the Sublicensees’ obligations to MOI with respect to Licensed Patent Rights but, in any event, will not be less than MOI’s obligations to KHH for such sublicenses under this Agreement. In
such event and subject to the preceding sentence, KHH will assume all the rights and obligations of MOI under such sublicenses with respect to the licenses granted under the Licensed Patents Rights and other Technology Rights to such Sublicensees.
In the event of such assignment, unless otherwise agreed by KHH, KHH will not be obligated to assume any obligation of MOI under the license agreement other than the granting of the license rights consistent with the terms hereof. 

5.4    Term of License.  The license grant in Section 5.1 will continue for the term
of this Agreement as set forth in Section 13.1, unless the Agreement is earlier terminated in accordance with Article 13 or otherwise. 

ARTICLE 6 
 ROYALTIES

 6.1    License Fee.  In consideration for the license rights granted herein, MOI will pay
KHH a license fee of [*****] for the licenses granted under this Agreement. Such license fee is payable as follows: 

(a)    [*****] of such fee is due within 15 days after the execution of this Agreement; 

(b)    [*****] of such fee is due within 15 days after satisfactory completion by KHH of the Diligence (as defined
in Section 8.3); provided that, unless this Agreement is sooner terminated, such fee is payable within 60 days of the Effective Date; and 

(c)    [*****] be paid within 75 days of the Effective Date, contingent on successful due diligence. 

6.2    Royalty on Sales of Products; Exclusions.  With respect to the Sale of Products by or for
MOI, and Affiliate of MOI, a Sublicensee, or and Affiliate of a Sublicensee, MOI will pay KHH [*****] of Net Revenues based on such Sale in such country. No more than one royalty payment will be due with respect to a Sale of a particular Product. No
multiple royalties will be payable because any Product, or its manufacture, sale or use is covered by more than one Valid Claim in a given country. No royalty will be payable under this Section with respect to (a) Sales of Products among MOI,
its Sublicensees or Affiliates, provided that the Sublicensees or Affiliates are not end users of the Product, or (b) Products distributed for use in research and/or development or as promotional samples or otherwise distributed without charge
to Third Parties. 
 6.3    Maximum Amount; Duration of Royalty Obligation.  Notwithstanding any
other term of this Agreement, MOI is not obligated to pay KHH any royalties, license fees or other amounts under this Article or Article 10, including royalties based on MOI or Sublicensee Product Sales, in excess of [*****] (the
“Maximum Amount”). Subject to the immediately preceding sentence, royalties due under this Article will be payable in U.S. Dollars on a country-by-country and Product-by-Product basis until the expiration of the Term of this
Agreement. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

 6.4    Minimum Royalties.  If MOI pays to KHH,
royalties, service fees and other amounts, pursuant to this Article or Article 10, in calendar years 2007, 2008 and 2009, less than [*****] then within 30 days of the end of such year MOI must pay KHH such shortfall. MOI will be entitled
to credit the amount of any payment of the shortfall made under this Section against any future actual royalty amounts owed pursuant to Section 6.2 or 10.4. 

6.5    Expenses.  Independent of the foregoing royalty obligations, MOI shall be responsible for payment
of all reasonable and pre-approved expenses of KHH in fulfilling its obligations to MOI under this Agreement. 
 ARTICLE 7 

REPORTS, PAYMENTS AND RECORD 

7.1    Reports; Payment.  Following the first Sale of a Product, on or before the 30th day after the end of each MOI fiscal quarter, and for so long as royalties are payable under this Agreement, MOI will render to KHH a report in writing, setting forth Net Revenues and the number of
units of Products Sold in each country during such quarter by MOI and Sublicensees. MOI will pay to KHH with each such report any royalties due to KHH as indicated in such report. 

7.2    Currency Exchange; Overdue Interest.  Net Revenues received by MOI from Sublicensees in
currencies other than U.S. dollars will be converted into U.S. dollars according to MOI’s reasonable standard internal conversion procedures. Overdue payments under this Agreement will bear interest from the date due until paid at the lower of
a per annum rate 1% above the prime rate in effect as published in the Wall Street Journal or at the highest interest rate permissible under applicable law. 

7.3    Records; Audit.  MOI will keep complete and accurate records and books of account in
respect of all Products made and sold by MOI, its Affiliates and Sublicensees, under this Agreement, and, of all payment obligations to KHH under this Agreement. KHH will have the right, during business hours, no more often than annually unless
there is breach of this Agreement by MOI to engage a nationally-certified auditing firm reasonably acceptable to MOI to examine such records and books of MOI its Sublicensees and Affiliates to verify the amounts paid to KHH hereunder. MOI will keep
the same for at least 3 years after it pays KHH the royalties due for such Products. Such auditors will not disclose to KHH or to any third party any information learned through such examination. However, if MOI challenges any finding of
underpayment, the auditors may disclose to KHH such information as is necessary to justify the auditors’ conclusions. KHH will not use any such information for any purpose other than determining and enforcing its rights under this Agreement. If
KHH’s examination of such records and books reveals any underpayment greater than 4% of the amount actually paid to KHH in the relevant time period, MOI will promptly pay to KHH the amount of such underpayment, and MOI will pay to KHH the
reasonable costs and expenses incurred by KHH in connection with such examination. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

 ARTICLE 8 

TRANSFER AND DILIGENCE 

8.1    Transfer.  Within 60 days of the Effective Date, KHH will deliver to MOI the following:

 (a)    A separate tangible description of all KHH and BASF Technology Rights and copies of all related
contracts, including the method of manufacture and formulation of the Products except for “Assignee Information” as defined in the Agro Kanesho License Agreement. 

(b)    All original or scanned (electronic) original documents and correspondence related to the Registration
application filed by KHH with the United States Environmental Protection Agency with respect to technical registration of Reynoutria sachalinensis (REYSA)/Polygonum sachalinensis (POLSA), the Manufacturing Use Product, and the
formulated product Milsana® bioprotectant Concentrate (collectively, the “Registration Application”). 

(c)    All trademark and patent documents. 

(d)    Efficacy data. 

(e)    All documents relating to plant production, formulation experimentation and final formulas 

8.2    Consulting Services.   MOI will pay KHH $100.00 per hour of expert consulting services by
KHH personnel to facilitate the transfer under Section 8.1 and to otherwise assist MOI in the development of the Product; provided that MOI is not obligated to pay KHH more than a combined total of [*****], accumulated in 2007 and
2008 for such services, unless MOI requests more than [*****] hours of services, at which time the parties will mutually agree to a per hour price. The parties will mutually agree on the timing and scope of the services to be provided by KHH under
this Section. The fees for such consulting services will be due 30 days after MOI’s receipt of the related invoice, which must be accompanied by detailed description of the services. In addition, MOI will be responsible for reimbursing KHH for
all reasonable out-of-pocket, pre-approved expenses related to the provision of such services. The foregoing fee represents the entire amount MOI is obligated to pay to KHH for such services. 

8.3    Diligence.  MOI may perform a due diligence investigation relating to the Technology
Rights, the potential Products and the related business prospects (the “Diligence”). MOI’s start of diligence is when patents, trademarks, EPA registration documents and production information have been received. If within
sixty (60) days after receipt of this information, MOI determines that any aspect of the Technology Rights or the potential Products are not satisfactory, then MOI may terminate this Agreement upon 15 days’ notice to KHH. However, prior to
so terminating this Agreement MOI shall first engage in good faith negotiations with KHH to modify the terms of this Agreement in order to reasonably address such unsatisfactory matters. If MOI finds something in its due diligence that requires
termination, then MOI will be entitled to a fee refund of its initial [*****]. 

8.4    Assignment.  KHH hereby assigns to MOI all of KHH’s right title and interest in and to
the Registration Application provided that such rights, title and interest shall revert if this Agreement is terminated for any reason. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

 ARTICLE 9 

PROPRIETARY RIGHTS 

9.1    Registrations; Improvements.  MOI is entitled to submit all regulatory filings in its name
and shall own all such filings and other registrations, including the Registrations. Any improvements to the Licensed Patent Rights or any other Technology Rights, whether patentable or not, made by MOI shall be the sole property of MOI. 

9.2    MOI Trademarks.  MOI will obtain and maintain trademarks for the Product as MOI sees fit at
MOI’s sole discretion and at its own expense. MOI will retain sole and exclusive ownership of such trademarks at all times. Nothing in this Agreement shall be construed as conferring on KHH the right to use in advertising, publicity or other
promotional activities any name, trademark or tradename of MOI or its products. 
 9.3    Publicity.  
MOI may publicize the relationship under this Agreement as provided in Section 15.9. 
 ARTICLE 10 

INFRINGEMENT BY THIRD PARTY 

10.1    Right to Defend.  As between KHH and MOI, MOI will at its expense, have the first right
but not the obligation to protect the Licensed Patent Rights and other Technology Rights from infringement and prosecute infringers. If KHH supplies MOI with evidence of infringement of Licensed Patent Rights or other Technology Rights, KHH may by
written notice request MOI to take steps to enforce such intellectual property rights. If KHH does so, and MOI does not, within 90 days of the receipt of such notice, either (a) cause the infringement to terminate, or (b) initiate and
continue a legal action against the infringer, KHH may, upon written notice to MOI, initiate an action against the infringer at KHH’s Notwithstanding the foregoing, MOI will have the right to sublicense any alleged infringer pursuant to
Article 5. 
 10.2    Declaratory Judgment.  If a declaratory judgment action or claim or
counterclaim alleging invalidity, unenforceability or noninfringement of any of the Licensed Patents or other Technology Rights is brought against KHH or MOI, MOI may elect to have sole control of the action, and if MOI so elects it will bear all
the costs of the action. 
 10.3    Cooperation in an Action.  If one party institutes or
carries on a legal action pursuant to Section 10.1 or 10.2, the other party will fully cooperate with and supply all assistance reasonably requested by the party instituting or carrying on such action, including, if requested by the
party instituting the action and necessary to pursue the action, joining in such action at the expense of the party requesting such joinder. A party instituting or carrying on such an action will keep the other party informed of the progress of such
action. Such other party will be entitled to be represented by counsel in connection with such action at its own expense. 

10.4    Allocation of Recovery and Expenses.   Any amounts paid to KHH or MOI by third parties as
the result of an action brought by either party pursuant to Section 10.1 or 10.2 (such as in satisfaction of a judgment or pursuant to a settlement), will first be applied to reimbursement of the unreimbursed expenses (including
attorneys’ fees and expert fees) incurred by each party. If this Agreement has not been terminated and the recovery is in the form of lost 

 revenues, then any remainder of the recovery after expenses shall be paid first to KHH as provided in Article 6.
If this Agreement has not been terminated and the recovery is in the nature of lost profits, then the parties will in good faith impute the amount of Net Revenues which would have generated such profits, and the amounts to be paid under Article 6
shall be paid to KHH with respect to such imputed Net Revenues, with the remainder in either case to be paid to MOI. 
 ARTICLE 11

 CONFIDENTIALITY 

11.1    Scope.  During the term of this Agreement and for 5 years thereafter, MOI and KHH agree:
(a) not to disclose to any third party, except as specifically allowed by this Agreement, any Confidential Information of the other party, and (b) to limit disclosure of Confidential Information within its own organization to individuals
whose duties justify the need to know such information and who are legally obligated to comply with the terms of this Agreement; provided, however, that nothing herein will limit disclosures by MOI in connection with MOI’s
exercise of its license rights as granted in Article 5, so long as the recipient is likewise bound by Confidentiality obligations at least as restrictive as Article 11. To the extent practical, Confidential Information will be
disclosed in tangible form and marked “Confidential.” Information disclosed in non-tangible form, such as orally or by visual inspection, will be considered confidential when the disclosing party confirms in writing the fact and general
nature of the disclosure within 1 month after it is made. 
 11.2    Exclusions.  The recipient
of Confidential Information will be under no obligation with respect to any information which: (a) at the time of disclosure is available to the public; (b) after disclosure becomes available to the public through no fault of the
recipient, provided that the obligation of the recipient will cease only after the date on which such information has become available to the public; (c) the recipient can demonstrate through tangible evidence was in its possession before
receipt from the disclosing party; (d) is disclosed to the recipient without restriction on disclosure by a third party who has the lawful right to disclose such information; or (e) was independently developed by the recipient as proven by
contemporaneous documentation made prior to the disclosure to recipient. Confidential Information will not be deemed to be within the foregoing exceptions merely because it is: (i) specific and embraced by more general information in the public
domain or the recipient’s possession or; (ii) a combination which can be pieced together to reconstruct the Confidential Information from multiple sources, none of which shows the whole combination, its principle of operation, or method of
use. 
 11.3    Required Disclosure.  It will not be a breach of this Article if the recipient
party is required to disclose the other party’s Confidential Information pursuant to an order of the government or a court of competent jurisdiction, provided that (a) the recipient party provides the other party with adequate
notice of the court or government order and the required disclosure, (b) the recipient party cooperates with the other party’s efforts to protect its Confidential Information with respect to such disclosure, and (c) the recipient
party takes all reasonable measures requested by the other party to challenge or to modify the scope of such required disclosure. 

 11.4    Terms of this Agreement.   Except as
expressly provided herein, MOI and KHH agree not to disclose any terms of this Agreement to any third party without the consent of the other party; provided, however, that disclosures may be made as required by securities or other
applicable laws, to actual or prospective investors and corporate partners, and to a party’s accountants, attorneys, and other professional advisors who agree to appropriate confidentiality provisions to protect such information from disclosure
or improper use, and by MOI to Sublicensees or potential Sublicensees. Also, nothing in this Agreement shall prevent MOI from providing to another customer MOI’s standard form agreements. 

ARTICLE 12 
 PATENTS AND
PATENT COSTS 
 12.1    Patent Costs.  Subject to the terms of Sections 12.2 and
13.3, from and after the Effective Date, MOI will pay for 100% of the patent costs incurred in connection with the Licensed Patent Rights, 

12.2    Responsible Party.  MOI will have the sole right to right to apply for, prosecute and
maintain, from the Effective Date through the termination of this Agreement, the Licensed Patent Rights and other Technology Rights. The application filings, prosecution, maintenance and payment of all fees and expenses, including legal fees,
relating to the Licensed Patent Rights will be the responsibility of MOI during such period, subject to Section 133. At MOI’s expense, KHH will provide MOI with all information necessary or useful for the filing and
prosecution of such Licensed Patent Rights and other Technology Rights and will cooperate fully with MOI so that MOI may establish and maintain such rights. Patent attorneys chosen by MOI will handle all patent filings and prosecutions, on behalf of
KHH, provided, however, KHH will be entitled to review and comment upon and approve, all material actions undertaken in the prosecution of all patents and applications. KHH will be deemed to have approved any such action if it fails to
disapprove such action within 10 business days of request for approval. KHH will promptly provide any comments or approvals which it elects to provide hereunder. If MOI declines to apply for, prosecute or maintain any Licensed Patent Rights and
other Technology Rights, KHH will have the right to pursue the same at KHH’s expense and MOI will have no rights under KHH’s interest therein nor any obligation to reimburse KHH for its related prosecution and maintenance fees. If MOI
decides not to apply for, prosecute or maintain any Licensed Patent Rights, MOI will give sufficient and timely notice to KHH so as to permit KHH to apply for, prosecute and maintain such Licensed Patent Rights. In such event, MOI will provide KHH
with all information necessary or useful for the filing and prosecution of such Licensed Patent Rights and will cooperate fully with KHH so that KHH may establish and maintain such rights. 

ARTICLE 13 
 TERM AND
TERMINATION 
 13.1    Term.  The term of this Agreement will commence on the Effective Date
and, unless earlier terminated in accordance with this Article, expire on the later of (a) the 10th anniversary of the Effective Date, or (b) the expiration of the last-to-expire issued
Valid Claim and any other patent issued relating to any other Technology Rights. 

 13.2    Termination by KHH.  KHH may terminate this
Agreement prior to the date it would otherwise expire pursuant to Section 13.1 if (a) MOI materially breaches this Agreement and fails to cure such breach within 60 days after notice from KHH of such breach, or (b) any
proceedings are instituted by or against MOI under any bankruptcy, insolvency, or moratorium law and such remain undismissed for at least 90 days. 

13.3    Termination by MOI.  MOI may terminate this Agreement prior to the date it would otherwise
expire pursuant to Section 13.1 if (a) KHH materially breaches this Agreement and fails to cure such breach within 60 days after notice from MOI of such breach, or (b) any proceedings are instituted by or against KHH under any
bankruptcy, insolvency, or moratorium law and such remain undismissed for at least 90 days. Also, MOI may terminate this Agreement as provided in Sections 8.3. 

13.4    Rights Regarding Products.  Notwithstanding anything herein to the contrary, following the
termination or expiration of the term of this Agreement, MOI will have the right to use or sell Products on hand on the date of such termination or expiration and to complete Products in the process of manufacture at the time of such termination or
expiration and use or sell the same, provided that MOI will submit the applicable royalty reports described in Sections 7.1, along with the royalty payments required above in accordance with Section 6.2 for Sale of such
Products. MOI may continue to sell Products to customers beyond the time period of the agreement. 

13.5    No Waiver of Claims; Assignment of Sublicenses.  Termination of this Agreement for any
reason will not release any either party from any liability which had accrued to the other party or which is attributable to a period prior to such termination. Upon any termination of this Agreement, KHH will accept an assignment by MOI of any
sublicenses granted by MOI to Sublicensees in accordance with Section 5.3, and any sublicense so assigned will remain in full force and effect 

13.6    Survival.  Termination of this Agreement will not relieve MOI of liability for payment of
any royalty due for Products made prior to the effective date of such termination. Also, Articles 2, 3, 4, 9, 11, 13, 14 and 15 will survive the expiration or termination of this Agreement for any reason. 

13.7    Return of Materials and Confidential Information. Upon termination of this Agreement for any reason, MOI
shall return to KHH all materials, Confidential Information, KHH Technology Rights and BASF Technology Rights, and MOI shall not use the same or any part thereof for any purpose whatsoever. 

13.8    Consequences of Termination. Subject to its rights under Sections 13.4, if applicable, if MOI terminates
this Agreement for any reason prior to 2016, it shall refrain, directly or indirectly, from the growing, production, marketing or distribution of Products anywhere within the Territory for two years after such termination, provided that MOI may
retain and continue to use such materials as necessary to exercise rights under Sections 13.4. 

 ARTICLE 14 

INDEMNITY 

14.1    MOI Indemnity.  MOI hereby agrees to defend, at its own expense, KHH from and against any
third party claim alleging, arising out of, or resulting from, (a) any breach of or inaccuracy in any representation or warranty made by MOI herein, or (b) the use or commercialization by MOI, its Sublicensees or assignees of the Licensed
Patent Rights or any other Technology Rights to the extent that any such claim arise solely from the actions of MOI. Subject to compliance with Section 14.3, MOI agrees to pay any damage or award finally awarded against KHH in such
action or agreed upon in settlement. 
 14.2    KHH Indemnity.  KHH agrees to defend MOI from
and against any third party claim alleging, arising out of, or resulting from, any breach of or inaccuracy in any representation or warranty made by KHH herein. Subject to compliance with Section 14.3, KHH agrees to pay any damage or award
finally awarded against MOI in such action or agreed upon in settlement. 

14.3    Process.  Any party obligated to provide indemnity under this Article must be
(a) notified promptly of any claims for which indemnity is sought and of which the applicable party has notice, (b) have the sole right to control and defend or settle any litigation within the scope of such party’s indemnity, and
(c) provided reasonable cooperation be the indemnified party in the defense of any such claims. 
 ARTICLE 15 

MISCELLANEOUS 

15.1    This Agreement will be governed by the laws of the State of California. 

15.2    Assignment.  This Agreement may not be assigned or otherwise transferred by any party
without the prior written consent of the other party; provided, however, that either party may assign this Agreement, without the consent of the other party (a) to any of its Affiliates, if the assigning party guarantees the full
performance of its Affiliate’s obligations hereunder, or (b) in connection with the transfer or sale of all or substantially all of the related assets or business or in the event of its merger or consolidation with another company. In all
cases the assigning party will provide the other party with prompt notice of any such assignment. No assignment will release a party from responsibility for the performance of any accrued obligation of such party hereunder. 

15.3    Notices.  All notices, requests or consents required or permitted under this Agreement
will be made in writing and will be given to the other party by personal delivery, registered or certified mail (with return receipt), overnight air courier (with receipt signature) or facsimile transmission (with “answerback” confirmation
of transmission), sent to such party’s address or telecopy numbers set forth below, or such other addresses or telecopy numbers of which the parties have given notice pursuant to this Section. Each such notice, request or consent will be deemed
effective upon the date of actual receipt, receipt signature or confirmation of transmission, as applicable. 
  

			
	If to MOI:	  	If to KHH:

			
	Marrone Organic Innovations, Inc.	  	KHH Biosci, Inc.
	 215 Madson Place, Suites B/C
 Davis, CA 95618
USA
 Attn: Dr. Pamela G. Marrone
 Phone:
(530) 750-2800
 Facsimile: (530) 750-2808
	  	 634 Lake Hogan Lane
 Chapel Hill, NC 27516
USA
 Attn: Dr. Hans von Amsberg
 [*****]

 15.4    Entire Agreement.   This Agreement constitutes the entire
agreement of the parties with respect to the subject matter herein and supersedes all prior agreements with respect thereto. This Agreement may be amended only in writing signed by both parties. 

15.5    Severability.  If a court or regulatory authority of competent jurisdiction determines
that one or more of the paragraphs or provisions of this Agreement are or may be invalid or unenforceable such decision will not affect the remainder of this Agreement. 

15.6    Force Majeure.  The parties will not be liable for any delay in or failure of
performance hereunder due to any contingency beyond its reasonable control including but not limited to an act of God, war, mobilization, insurrection, rebellion, civil commotion, riot, act of extremist or public enemy, sabotage, labor dispute,
lockout, strike, explosion, fire, flood, storm, accident, drought, equipment failure, power failure, shortage of cars, delay of carrier, embargo, law, ordinance, rule or regulation, whether valid or invalid, including priority requisition,
allocation, or price control. 
 15.7    Waiver.  Failure by either party hereto to exercise or
enforce any rights conferred upon it by this Agreement will not be deemed to be a waiver of any such rights or operate so as to bar the exercise or enforcement thereof or of any other rights at any subsequent time or times. 

15.8    Status of the Parties.  Nothing in this Agreement will be construed as to constitute a
partnership or joint venture between the parties or authorize either to represent the other party or contract any liability on behalf of the other party. 

15.9    Joint Press Release; Publicity.  Upon execution of this Agreement or as soon as
practicable thereafter, the parties will issue a joint press release, the text of which will be mutually acceptable to the parties. In addition, from time to time during the term hereof, MOI may issue press releases and other forms of publicity
referring to the Products and KHH’s role with respect thereto, such to be subject to the consent of KHH (such consent not to be unreasonably withheld or delayed). 

15.10    No Consequential Damages.  Except for claims arising out of breach of Article 11,
neither party will be liable to the other for any special, consequential, incidental, or indirect damages arising out of this agreement, however caused, under any theory of liability. 

15.11    Construction.  This Agreement is the result of negotiations among, and has been reviewed
by, KHH and MOI. Accordingly, this Agreement will be deemed to be the product of both parties, and no ambiguity will be construed in favor of, or against, KHH or MOI. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

 15.12    Other Interpretive Provisions.  References
in this Agreement to “Articles” and “Sections” are to articles and sections herein unless otherwise indicated. The words “include” and “including” and words of similar import when used in this Agreement will
not be construed to be limiting or exclusive. Except as provided in a particular context, the word “or” when used in this Agreement may mean each as well as all alternatives. Headings in this Agreement are for convenience of reference only
and are not part of the substance hereof. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed on the dates
indicated below but to be effective as of the Effective Date. 
  

									
	MARRONEORGANIC INNOVATIONS, INC.	 		 	KHH BIOSCI, INC.
					
	By:	 	/s/ Pamela Marrone	 		 	By:	 	/s/ Hans von Amsberg
	Name:	 	Pamela Marrone	 		 	Name:	 	Hans von Amsberg
	Title:	 	President & CEO	 		 	Title:	 	President KHH BioSci, Inc.
	Date:	 	May 21, 2007	 		 	Date:	 	May 22, 2007

 EXHIBIT C 

LICENSED PATENTS 
  

							
	 Country
	  	 Number
	  	 Status
	  	 Expiring

	USA	  	5,989,429	  	Granted	  	[On or around 2016]
	USA	  	4,863,734	  	Granted	  	Sept. 05, 2006 [Expired]
	Canada	  	1,292,679	  	Granted	  	Dec. 03, 2008 [Not maintained]
	South Africa	  	0088/7962	  	Granted	  	Oct. 25, 2008 [Not maintained]
	Australia	  	746341	  	Granted	  	November 5, 2018EX-10.26

 Exhibit 10.26 

LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (this “Agreement”)
is made and entered into effective as of December 28, 2009 (the “Effective Date”), by and between THE UNIVERSITY OF THE STATE OF
NEW YORK (“USNY”), a New York corporation maintaining offices at State Education Building – Room 121, Albany, New York 12234-1000, and MARRONE
BIO INNOVATIONS, INC. (“MBI”), a Delaware corporation maintaining offices at 2121 Second Street, Ste. B-107, Davis, California 95618. 

ARTICLE 1 
 BACKGROUND

 1.1        USNY has the right and the authority to grant certain
licenses to the patents, patent applications and other inventions listed in Exhibit A. 

1.2        MBI is desirous of obtaining, and USNY wishes to grant to MBI, an
exclusive license to the Licensed Patent Rights (as defined in Section 2.9) and the Technology Rights (as defined in Section 2.15) under the terms and conditions of this Agreement. 

ARTICLE 2 
 DEFINITIONS

 2.1        “Affiliates” means, with respect to a party, any
entity that controls, is controlled by, or is under common control with the party. For the avoidance of doubt, Affiliate, with respect to USNY includes without limitation the New York State Education Department (“NYSED”). 

2.2        “Confidential Technology” means the following:
(a) the detailed culturing (e.g., fermentation) protocols related to the Licensed Product; (b) the specific location in North America where [*****]; (c) detailed protocols (dosage, etc.) used for [*****] by either [*****]; and
(d) detailed protocols for [*****] to achieve higher [*****] than would be achieved by [*****]. 

2.3        “Confidential Information” means, as to either party and
without limitation, such party’s proprietary or confidential items including: Confidential Technology, data, know-how, formulas, compositions, processes, documents, designs, sketches, photographs, plans, graphs, drawings, specifications,
equipment, samples, reports, findings, inventions, ideas and information, including business information related to Licensed Products and the Technology Rights. 

2.4        “Customer” means any purchaser of a Licensed Product other
than USNY, MBI, or a Sublicensee. 
  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 1 

 2.5        “Deductible
Expenses” means the following items of expense incurred in connection with Sales of Licensed Products to the extent paid or allowed by MBI and/or a Sublicensee: (a) sales, use or turnover taxes; (b) excise, value added,
importation or other taxes, custom duties or consular fees; (c) transportation, freight, and handling charges, and insurance on shipments to customers; (d) trade, cash or quantity discounts or rebates to the extent actually granted
(including government-mandated rebates); (e) rebates, refunds, and credits for any rejected or returned Licensed Products or due to billing errors or because of retroactive price reductions, rebates or chargebacks; and (f) uncollected
accounts receivable attributable to Sales of Licensed Products. 

2.6        “Exclusive” means that for the term of this Agreement USNY
will not, in the Field, use or license to any licensee, other than MBI, the Licensed Patents or the Technology Rights. 

2.7        “EPA Registration” means a Section 3 approval by the
United States Environmental Protection Agency of a Licensed Product as a microbial pesticide. 

2.8        “Field” means applications or uses as a pesticide. 

2.9        “Licensed Patents” means: (i) all domestic and
foreign patents and patent applications listed in Exhibit A attached hereto; (ii) all divisionals, continuations, and continuations-in-part of the foregoing patent applications; (iii) all patents that issue on any of the foregoing
patent applications; (iv) all foreign counterparts of the foregoing patents and patent applications; and (v) all reissues, reexaminations, renewals, extensions, and supplementary protection certificates relating to any of the foregoing
patents. Exhibit A may be updated from time to time on mutual agreement. 

2.10        “Licensed Patent Rights” means any and all rights under
the Licensed Patents. 
 2.11        “Licensed Product” means any
product or device that is covered by, or is made by or utilizes a process or material covered by, the Licensed Patent Rights or based on the Technology Rights. 

2.12        “Net Revenues” means the amount received by MBI or a
Sublicensee, in each case for the Sale of a Licensed Product to a Customer, less the Deductible Expenses applicable to such Sale. 

2.13        “Sale” means the sale, transfer, exchange or other
commercial disposition of a Licensed Product, which shall include the use of such Licensed Product in a service performed for a Customer. In case of doubt, Sales of Licensed Products shall be deemed consummated no later than receipt of payment from
a Customer for the applicable transaction involving such Licensed Product. 

2.14        “Sublicensee” shall mean, with respect to a particular
Licensed Product, a third party to which MBI has granted a license or sublicense under any or all of the Licensed Patent Rights and/or any other Technology Rights. 

  
 2 

 2.15        “Technology
Rights” means all ideas, inventions, formulae, processes, trade secrets, know-how, intellectual property, techniques, methods, specifications, practices, data and other forms of information, including the Confidential Technology, relating
to the processes, methods and techniques for manufacturing, formulating and using the Licensed Patent Rights or relating to the Licensed Products, whether patentable or not and whether or not reduced to practice, including Licensed Patent Rights and
registration data, in each case owned or licensable or otherwise controlled by USNY or an Affiliate or directly or indirectly derived from the foregoing at any time during the term of this Agreement. For avoidance of doubt, Technology Rights do not
include research results, protocols or the like that relate only to biological strains or organisms other than those disclosed or covered by the Licensed Patents, whether or not such other biological strains or organisms could be used in the Field.

 2.16        “Territory” means the entire world. 

2.17        “Valid Claim” means, with respect to any country, a claim
of an issued patent within the Licensed Patents that has not, with respect to such country (a) expired or been canceled, (b) been declared invalid by an unreversed decision of a court or other appropriate body of competent jurisdiction
from which there can be no further appeal, (c) been admitted to be invalid or unenforceable through reexamination, reissue, disclaimer or otherwise, and/or (d) been abandoned in accordance with or as permitted by the terms of this
Agreement or by mutual written agreement. 
 ARTICLE 3 

REPRESENTATIONS, WARRANTIES AND COVENANTS OF USNY 

3.1        Corporate Power and Authority. USNY has the corporate power
and authority to execute and deliver this Agreement and perform its obligations hereunder. USNY also represents and warrants that it has the right and the authority, including ownership or appropriate and valid licenses, to grant the licenses set
forth in Article 5 and to grant and perform its other rights and obligations thereunder. 

3.2        Compliance with Law. USNY will conduct its activities and
operations under this Agreement in compliance with all applicable laws, statutes, rules or regulations. 

3.3        Ownership; No Conflicting Agreement. USNY represents and
warrants that it has the right to grant the licenses granted under this Agreement, that it has joint title and co-ownership of the Licensed Patent Rights and the Technology Rights with two co-owners, that it has obtained rights in the Field from one
such co-owner of the Licensed Patent Rights and the Technology Rights and that to the best of USNY’s knowledge neither such co-owner nor any other joint or co-owner has granted to any third party any right or interest in any of the Licensed
Patent Rights or other Technology Rights in the Field. USNY represents and warrants that it has not granted, and no Affiliate has granted, to any third party any right or interest in any of the Licensed Patent Rights or other Technology Rights that
is inconsistent with the rights granted to MBI herein, and neither USNY or any Affiliate will grant any third party such a right during the term of this Agreement. 

  
 3 

 3.4        No Litigation.
USNY represents and warrants that, as of the Effective Date, there are no pending or, to its or its Affiliates knowledge, threatened actions, suits, investigations, claims, or proceedings in any way relating to the Licensed Patent Rights or other
Technology Rights. 
 ARTICLE 4 

REPRESENTATIONS, WARRANTIES AND COVENANTS OF MBI 

4.1        Corporate Power and Authority. MBI has the corporate power
and authority to execute and deliver this Agreement and perform its obligations hereunder. 

4.2        Compliance with Law. MBI will conduct its activities and
operations under this Agreement in compliance with all applicable laws, statutes, rules or regulations. 

4.3        Commercialization. MBI will use its best efforts to
commercialize the Licensed Products. MBI will not provide Licensed Products at less than fair market value in order to intentionally avoid the royalties required hereunder or in order to intentionally induce purchase of other products or services of
MBI; provided, however, that nothing herein shall prohibit or impair the right of MBI to distribute Licensed Products at other than fair market value for use in research and/or development, as promotional samples, for testing,
demonstrations or trials or otherwise to third parties to promote Sales. 

4.4        Patent Coverage and Validity. MBI will not contest the
validity of the Licensed Patents or the coverage of the Licensed Patents of MBI’s Licensed Products as currently planned, nor will MBI intentionally assist any third party, including any Sublicensee, in doing so. 

ARTICLE 5 
 PATENT
LICENSE GRANT 
 5.1        Grant. Subject to the terms and
conditions of this Agreement, USNY hereby grants to MBI an Exclusive, royalty-bearing, sublicensable license (or sublicense, as applicable) in the Field, under the Licensed Patent Rights and any other Technology Rights, to research, develop, make,
have made, import, have imported, use, have used, sell, have sold, offer for sale, have offered for sale, and otherwise exploit Licensed Products in the Territory and in the Field. 

5.2        Exceptions. The license grant in Section 5.1 is
subject only to the reservation of USNY’s and NYSED’s rights: (a) to make, have made or use the Licensed Patent Rights and Technology Rights for USNY’s and NYSED’s research and educational purposes only (including such USNY
or NYSED research sponsored or funded by non-profit or government entities) but not to assist or support any other party in connection with any commercial use in the Field and not for sale or other distribution to third parties for commercial use in
the Field; and (b) to make, have made, use or license the Licensed Patent Rights and Technology Rights for use outside the Field. Consistent with the foregoing limited exception, USNY or NYSED may, and until January 1, 2010 as between
themselves and MBI shall have the exclusive right to, submit the results of their research underlying the Licensed Patent Rights and Technology Rights in 

  
 4 

 
reputable scientific journals or at scientific conferences; provided, however, that, at all times prior to January 1, 2010 and thereafter, MBI shall be furnished with a copy of
any proposed publication, paper or any other oral or written disclosure prior to submission for publication or disclosure to a third party and for limitation as provided below. In the case of abstracts, MBI shall be given a copy at least seven
(7) days prior to the earlier of submission or disclosure; in all other cases MBI shall be given such material at least fifteen (15) days prior to the earlier of submission or disclosure to third parties. At the end of such 7 or 15 day
period USNY or NYSED may proceed with submission or disclosure unless MBI has notified NYSED (or USNY) that in MBI’s reasonable opinion, supported by evidence, the submission or disclosure may describe or relate to inventions, materials or
discoveries made by MBI or USNY or Affiliates which MBI believes may be patentable and for which no patent application has been filed, or which is a trade secret or other confidential material the disclosure of which may be adverse to MBI’s
commercialization of the Licensed Product. If MBI has made such notification, then USNY or NYSED shall, as reasonably notified by MBI, edit such submission or disclosure, redact from such submission or disclosure any such material or refrain from
making such submission or disclosure; provided, however, that USNY or NYSED may elect to refrain from publishing such confidential material rather than publishing a redacted version. Without limitation to the foregoing, MBI, USNY and
NYSED and any of their Affiliates will not publish or otherwise make public the following information: (a) the detailed culturing (e.g., fermentation) protocols related to the Licensed Product; (b) the specific location in North America
where the bacterial strain was originally isolated; (c) the detailed protocols (dosage, etc.) used for killing the cells by either e-beaming or gamma ionizing radiation; or (d) the detailed protocols for combining supernatant with cells to
achieve higher dreissenid mortality than would be achieved by just cells alone; provided, however, that nothing herein will limit confidential disclosures by MBI in connection with MBI’s exercise of its license rights as granted
above. 
 5.3        Limits on Sublicensing. MBI has the right to
grant nonexclusive or exclusive sublicenses hereunder, provided, that: (a) MBI shall pay royalties on all Net Revenues of Sublicensees to USNY in accordance with Article 6; (b) MBI may grant sublicenses of no greater scope
than the licenses granted under Section 5.1; (c) MBI shall inform USNY of any proposed sublicenses; and (d) MBI shall not enter into a sublicense with any party that is barred from contracting with the State of New York

 5.4        Assignment of Sublicenses. Any sublicenses granted by
MBI of the rights it receives under Section 5.1, including any nonexclusive sublicenses, will remain in effect and, at MBI’s election, may be assigned to USNY if the license in Section 5.1 terminates pursuant to
Article 12, provided the financial obligations of each Sublicensee to USNY will be at least the same as the Sublicensee’s obligations to MBI with respect to Licensed Patent Rights but, in any event, will not be less than MBI’s
obligations to USNY for such sublicenses under this Agreement and provided that USNY has been provided with a copy of any sublicense agreement, USNY finds the terms of such agreement reasonably acceptable and any Sublicensee to be assigned agrees to
comply with all of the terms of this Agreement. For avoidance of doubt, USNY may reject assignment of a sublicense if USNY reasonably concludes that MBI or the Sublicensee has not provided adequate assurance of the capability of the Sublicensee to
satisfy the financial obligations of this Agreement. In such event and subject to the preceding 

  
 5 

 
sentences, and provided that any such Sublicensees are not barred from contracting with the State of New York, USNY will assume all the rights and obligations of MBI under such sublicenses with
respect to the licenses granted under the Licensed Patents Rights and other Technology Rights to such Sublicensees. In the event of such assignment, unless otherwise agreed by USNY, USNY will not be obligated to assume any obligation of MBI under
the license agreement other than the granting of the license rights consistent with the terms hereof. 

5.5        Term of License. The license grant in Section 5.1
shall continue for the term of this Agreement as set forth in Section 12.1, unless the Agreement is earlier terminated in accordance with Article 12 or otherwise. 

ARTICLE 6 
 ROYALTIES

 6.1        Licensee Fee. Subject to the terms and conditions of
this Agreement, MBI will pay USNY a license fee for the licenses granted under this Agreement. Such license fee shall be payable as follows: 

(a)        [*****] of such fee is due within [*****] after the Effective Date
of this Agreement; and 
 (b)        [*****] of such fee is due within
[*****] after satisfactory receipt by MBI of the first EPA Registration. 

6.2        Royalty on Sales of Licensed Products; Exclusions. With
respect to the Sale after the Effective Date of Licensed Products by or for MBI in the United States or Canada where a Valid Claim in the Field remains in such country (“North American Valid Claims”), MBI shall pay USNY [*****] of
Net Revenues based on such Sale in such country. With respect to the Sale after the Effective Date of Licensed Products by or for MBI in any other country, if and to the extent a North American Valid Claim in the Field remains, MBI shall pay USNY
[*****] of Net Revenues based on such Sale in such country. With respect to the Sale after the Effective Date of Licensed Products by or for MBI in any country, where no North American Valid Claim in the Field remains, MBI shall pay USNY [*****] of
Net Revenues based on such Sale in any such country during the term of this Agreement. No more than one royalty payment will be due with respect to a particular Sale of a Licensed Product. No multiple royalties will be payable because any Licensed
Product, or its manufacture, sale or use is covered by more than one Valid Claim in a given country. No royalty will be payable under this Section with respect to (a) Sales of Licensed Products among MBI and its Sublicensees, provided that the
Sublicensees are not end users of the Licensed Product and provided MBI pays USNY royalties owing on Net Revenues of such Sublicensees, or (b) Licensed Products distributed for use in research and/or development or as promotional samples or
otherwise distributed without charge to third parties to promote Sales of Licensed Products. 

6.3        Maximum Amount; Duration of Royalty Obligation.
Notwithstanding any other term of this Agreement, MBI is not obligated to pay USNY any royalties, license fees or other amounts under this Article or otherwise, including royalties based on MBI or Sublicensee Licensed Product Sales but excluding the
license fees described in Section 6.1, in excess of [*****]. Subject to the immediately preceding sentence, royalties due under this Article will 
  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 6 

 
be payable in U.S. Dollars on a country-by-country and Licensed Product-by-Licensed Product basis until the end of the term of this Agreement. 

6.4        Currency Exchange. For the purpose of determining royalties
payable under this Agreement, any royalties or other revenues MBI receives in currencies other than U.S. dollars and any Net Revenues denominated in currencies other than U.S. dollars shall be converted into U.S. dollars according to MBI’s
reasonable standard conversion procedures (which shall be based on a readily available published rate). 
 ARTICLE 7 

PROPRIETARY RIGHTS 

7.1        Registrations; Improvements. MBI is entitled to submit all
regulatory filings in its name and shall own all such filings and other registrations, including the EPA Registrations and Canadian PMRA (Pest Management Regulatory Agency) registrations. USNY and its Affiliates shall provide MBI with all
information reasonably necessary or useful for such filings and registrations and shall cooperate with MBI so that MBI may make and maintain such filings and registrations. Prior to March 1, 2010, USNY’s and its Affiliates’
obligations under the preceding sentence shall be at USNY’s cost, and from and after March 1, 2010, USNY and its Affiliates shall be reimbursed for reasonable and customary expenses USNY and its Affiliates actually incur thereafter in
performing such obligation provided that such expenses are first disclosed to MBI. Any improvements to the Licensed Patent Rights or any other Technology Rights, whether patentable or not, made by MBI shall be the sole property of MBI. 

7.2        MBI Trademarks. MBI will obtain and maintain trademarks for
the Licensed Products as MBI sees fit at MBI’s sole discretion and at its own expense. MBI will retain sole and exclusive ownership of such trademarks at all times. Nothing in this Agreement shall be construed as conferring on USNY the right to
use in advertising, publicity or other promotional activities any name, trademark or tradename of MBI or its products; provided, however; in the event of an assignment of a sublicense from MBI to USNY in accordance with
Section 5.4 of this Agreement, USNY shall have the limited right to use the MBI trademarks solely in connection with a sale, transfer, exchange or other commercial disposition of Licensed Products that use such MBI trademarks and are already
manufactured at the time of such assignment of a sublicense if, and only to the extent, necessary to effect such sale, transfer, exchange or other commercial disposition. 

ARTICLE 8 
 INFRINGEMENT
BY THIRD PARTY 
 8.1        Right to Defend. As between USNY and
MBI, MBI shall at its expense, have the first right but not the obligation to protect the Licensed Patent Rights and other Technology Rights from infringement and prosecute infringers when, in its sole judgment, such action may be reasonably
necessary, proper and justified in order to maintain the value of MBI’s rights in the Field. If USNY shall have supplied MBI with evidence of infringement of Licensed Patent Rights, or other Technology Rights. USNY may by written notice request
MBI to take steps to enforce such intellectual property rights. If USNY does so, and MBI does not, within one hundred eighty (180) days of the receipt of such notice, either (a) cause the infringement to

  
 7 

 
terminate, or (b) initiate and continue a legal action against the infringer, USNY may, upon written notice to MBI, initiate an action against the infringer at USNY’s expense.
Notwithstanding the foregoing, MBI shall have the right to sublicense any alleged infringer pursuant to Article 5. 

8.2        Declaratory Judgment. In the event that a declaratory
judgment action or claim or counterclaim alleging invalidity, unenforceability or noninfringement of any of the Licensed Patents or other Technology Rights related to the Field shall be brought against USNY or MBI, MBI may elect to have control of
the action, and if MBI so elects it shall bear all the costs of the action; provided, however, that if such action, claim or counterclaim materially and adversely impacts rights outside the Field reserved to USNY or its Affiliates or licensed to a
third party, then USNY, the Affiliate, or the licensee shall have the right to participate in the action, claim or counterclaim, to comment on the defense or settlement of any such action, claim or counterclaim and their own expense, and to approve
(such approval not be unreasonably withheld or delayed) any settlement of such action, claim or counterclaim that would have a material adverse impact on the Licensed Patent Rights or Technology Rights outside the Field reserved to USNY or its
Affiliates. 
 8.3        Cooperation in an Action. In the event one
party shall institute or carry on a legal action pursuant to Section 8.1 or 8.2, the other party shall fully cooperate with and supply all assistance reasonably requested by the party instituting or carrying on such action,
including (a) by using commercially reasonable efforts to have its employees testify when requested and to make available relevant records, papers, information, samples, specimens, and the like, and (b) if requested by the party
instituting the action and necessary to pursue the action, joining in such action at the expense of the party requesting such joinder. A party instituting or carrying on such an action shall keep the other party informed of the progress of such
action, and said other party shall be entitled to be represented by counsel in connection with such action at its own expense. 

8.4        Allocation of Recovery. Any amounts paid to USNY or MBI by
third parties as the result of an action brought by either party pursuant to Section 8.1 or 8.2 (such as in satisfaction of a judgment or pursuant to a settlement), shall first be applied to reimbursement of the unreimbursed expenses
(including attorneys’ fees and expert fees) incurred by each party. Any remainder of the amount paid to MBI or USNY shall be divided between the parties as follows: (a) if such amount was paid to USNY, fifty percent (50%) of such
remainder shall be retained by USNY and the balance shall be paid to MBI; or (b) if such amount was paid to MBI, such remainder shall be deemed to be Net Revenues for Sale of Licensed Products and MBI shall pay to USNY royalties on such amounts
pursuant to Section 6.2. 
 ARTICLE 9 

RECORDS, REPORTS AND PAYMENTS 

9.1        Records; Audit. MBI shall keep complete and accurate records
and books of account in respect of all Licensed Products made and sold by MBI and of all payment obligations to USNY hereunder. MBI shall keep the same for at least six (6) years after it pays USNY the royalties due for such Licensed Products.
USNY shall have the right, during business hours, no more often than annually, to engage, at its own expense (other than as provided in the last sentence of this Section) a nationally-certified auditing firm reasonably acceptable to MBI to

  
 8 

 
examine such records and books to verify the amounts paid to USNY hereunder. Such auditors shall not disclose to USNY or to any third party any confidential information learned through an
examination of such records and books, except for any information showing a discrepancy in amounts owed to USNY, and USNY shall not use any such information for any purpose other than determining and enforcing its rights under this Agreement. In the
event that USNY’s examination of such records and books reveals any underpayment greater than ten percent (10%) of the amount actually paid to USNY in the relevant time period, MBI shall promptly pay to USNY the amount of such
underpayment, and MBI shall pay to USNY the reasonable costs and expenses incurred by USNY in connection with such examination. 

9.2        Reports; Payment. Following the first Sale of a Licensed
Product, on or before the day that is sixty (60) days after the end of each MBI fiscal quarter, and for so long as royalties are payable under this Agreement, MBI shall render to USNY a report in writing setting forth Net Revenues and the
number of units of Licensed Products Sold in each country during such quarter by MBI and Sublicensees during the preceding fiscal quarter (to the extent royalties are payable to USNY based on such revenues). Each such report shall also set forth an
explanation of the calculation of the royalties payable hereunder and be accompanied by payment of the royalties shown by said report to be due USNY, as well as payment of any underpayment in any prior period revealed by any audit by MBI or USNY.
Notwithstanding the foregoing, if (a) USNY materially breaches this Agreement, (b) MBI gives USNY written notice of the breach, and (c) USNY has not cured the breach by the time a payment is due under this Section 9.2,
then MBI may make the required payment into an interest bearing escrow account to be released to USNY when the breach is cured, less any damages that are payable to MBI by virtue of USNY’s breach. 

ARTICLE 10 

CONFIDENTIALITY 

10.1        Scope. During the term of this Agreement and for 5 years
thereafter, MBI and USNY agree: (a) not to disclose to any third party, except as specifically allowed by this Agreement, any Confidential Information of the other party, and (b) to limit disclosure of the other party’s Confidential
Information within its own organization to individuals whose duties justify the need to know such information and who are legally obligated to comply with the terms of this Agreement; provided, however, that nothing herein will limit
disclosures by MBI in connection with MBI’s exercise of its license rights as granted in Article 5, and provided, further, that nothing herein will limit disclosures among USNY and NYSED or to persons working with USNY or
NYSED on research outside the Field and who have signed a confidentiality statement agreeing to abide by the terms of Article 10 of this Agreement. To the extent practical, Confidential Information will be disclosed in tangible form and
marked “Confidential.” Information disclosed in non-tangible form, such as orally or by visual inspection, will be considered confidential when the disclosing party confirms in writing the fact and general nature of the disclosure within 1
month after it is made. 
 10.2        Exclusions; Required
Disclosure. The recipient of Confidential Information will be under no obligation with respect to any information which: (a) at the time of disclosure is available to the public; (b) after disclosure becomes available to the public
through no fault of the recipient, provided that the obligation of the recipient will cease only after the date on which 

  
 9 

 
such information has become available to the public; (c) the recipient can demonstrate through tangible evidence was in its possession before receipt from the disclosing party; (d) is
disclosed to the recipient without restriction on disclosure by a third party who has the lawful right to disclose such information; or (e) was independently developed by the recipient as proven by contemporaneous documentation made prior to
the disclosure to recipient. It shall not be a breach of this Article 10 if the recipient party is required to disclose the other party’s Confidential Information pursuant to an order of the government or a court of competent
jurisdiction or by state or federal law or regulation including but not limited to the Freedom of Information Act, provided that (a) the recipient party provides the other party with adequate notice of the court or government order or
legal disclosure request and the required disclosure, (b) the recipient party cooperates with the other party’s efforts to protect its Confidential Information with respect to such disclosure, and (c) the recipient party takes all
reasonable measures requested by the other party to challenge or to modify the scope of such required disclosure. 

10.3        No Third Party Disclosure. Except as expressly provided
herein, MBI and USNY agree not to disclose any terms of this Agreement to any third party without the consent of the other party; provided, however, that disclosures may be made as required by securities or other applicable laws, or to
actual or prospective investors or corporate partners, or to a party’s accountants, attorneys, other professional advisors who agree to appropriate confidentiality provisions to protect such information from disclosure or improper use, and by
MBI to Sublicensees or potential Sublicensees. 
 ARTICLE 11 

PATENTS AND PATENT COSTS 

11.1        Patent Costs. Subject to the terms of
Section 11.2, with respect to patent costs paid by USNY in connection with the preparation, filing, prosecution, issuance and maintenance of the Licensed Patents in the Territory, MBI shall pay to USNY [*****] of such patent costs that
are incurred from and after the Effective Date. 
 11.2        Responsible
Party. MBI shall have the sole right to apply for, prosecute and maintain, from the Effective Date through the termination of this Agreement, the Licensed Patent Rights. The application filings, prosecution, maintenance and payment of all fees
and expenses, including legal fees, relating to the Licensed Patent Rights shall be the responsibility of MBI during such period. USNY shall provide MBI with all information necessary or useful for the filing and prosecution of such Licensed Patent
Rights and shall cooperate fully with MBI so that MBI may establish and maintain such rights. Patent attorneys chosen by MBI and approved by USNY shall handle all patent filings and prosecutions, on behalf of USNY, provided, however,
USNY shall be entitled to review and comment upon and approve, all material actions undertaken in the prosecution of all patents and applications; provided that USNY will be deemed to have approved any such action if it fails to disapprove
such action within one month of notice per Section 3.5 of such request for approval. USNY shall promptly provide any comments or approvals which it elects or is required to provide hereunder. If MBI declines to apply for, prosecute or
maintain any Licensed Patent Rights, USNY shall have the right to pursue the same at USNY’s expense and MBI shall have no rights under USNY’s interest therein nor any obligation to reimburse USNY for its related prosecution and maintenance
fees. If MBI 
  

	 [*****]
	 Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 10 

 
decides not to apply for, prosecute or maintain any Licensed Patent Rights, MBI shall give sufficient and timely notice to USNY so as to permit USNY to apply for, prosecute and maintain such
Licensed Patent Rights. In such event, MBI shall provide USNY with all information necessary or useful for the filing and prosecution of such Licensed Patent Rights and shall cooperate fully with USNY so that USNY may establish and maintain such
rights. 
 ARTICLE 12 

TERMINATION 

12.1        Term and USNY Termination. The term of this Agreement shall
commence upon the Effective Date and, unless earlier terminated in accordance with this Article 12, expires upon the later of (a) the expiration of the last-to-expire issued Valid Claim or (b) December 31, 2017. USNY shall have
the right, subject to Section 12.2, to terminate this Agreement prior to the date it would otherwise expire pursuant to this Section 12.1 if: (a) MBI materially breaches this Agreement and fails to cure such breach
within sixty (60) days after notice from USNY of such breach or (b) any proceedings are instituted by or against MBI under any bankruptcy, insolvency, or moratorium law and such remain undismissed for at least 90 days. 

12.2        Cure Right; No Waiver. USNY may exercise its right of
termination under Section 12.1 by giving MBI, its trustees or receivers or assigns, sixty (60) days prior written notice of USNY’s election to terminate, which notice shall specify the basis for (and facts supporting)
USNY’s right to terminate. Upon the expiration of such period, this Agreement shall automatically terminate unless MBI has previously cured the breach or condition permitting termination under Section 12.1, in which case this
Agreement shall not terminate; provided, however, that if MBI receives notification from USNY of a material breach and if MBI notifies USNY in writing within thirty (30) days of receipt of such default notice that MBI disputes the asserted
default, the matter will be submitted to arbitration as provided in Section 13.4 of this Agreement. In such event, USNY shall not have the right to terminate this Agreement until it has been determined in such arbitration proceeding that
MBI materially breached this Agreement and MBI fails to cure such breach within ninety (90) days after the conclusion of such arbitration proceeding. Such notice and termination shall not prejudice USNY’s rights to any royalties and other
sums due hereunder and shall not prejudice any cause of action or claim of USNY accrued or to accrue on account of any breach or default by MBI. Upon any termination of this Agreement USNY shall accept an assignment by MBI of any sublicenses granted
by MBI to Sublicensees, subject to such Sublicensee’s eligibility to contract with the State of New York and subject to approval by USNY, such approval to not be unreasonably withheld, and any sublicense so assigned shall remain in full force
and effect. The failure of USNY at any time, or for any period of time, to enforce any of the provisions of this Agreement shall not be construed as a waiver of such provisions or the right of USNY thereafter to enforce each and every such
provision. 
 12.3        MBI Termination. MBI shall have the right to
terminate this Agreement prior to the date it would otherwise expire if USNY materially breaches this Agreement and fails to cure such breach within sixty (60) days after notice from MBI of such breach. 

  
 11 

 12.4        No Effect on
Accrued Payment Obligations.   No termination of this Agreement shall relieve MBI of the liability for payment of any royalty due for Licensed Products made prior to the effective date of such termination. 

12.5        Rights Regarding Licensed Products.  
Notwithstanding anything herein to the contrary, in the event of any termination or expiration of the term of this Agreement, MBI shall have the right to use or sell Licensed Products on hand on the date of such termination or expiration and to
complete Licensed Products in the process of manufacture at the time of such termination or expiration and use or sell the same, provided that MBI shall submit the applicable royalty reports described above, along with the royalty payments
required above for Sale of such Licensed Products. 
 12.6        No
Waiver of Claims.   Termination of this Agreement for any reason shall not release any party hereto from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period
prior to such termination, nor preclude either party from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to such termination. 

12.7        Survival.   Articles 6.3, 7, 9, 10, 12 and
13 of this Agreement shall survive the expiration or termination of this Agreement for any reason. 
 ARTICLE 13 

MISCELLANEOUS 

13.1        Entire Agreement; Amendment. This Agreement sets forth the
complete agreement of the parties concerning the subject matter hereof and may not be contradicted by evidence of any prior or contemporaneous agreement between the parties concerning the subject matter of this Agreement. No waiver of or amendment
of any of the terms hereof shall have any force or effect unless in writing, signed by duly authorized representatives of the parties. 

13.2        Assignment.   This Agreement may not be assigned
or otherwise transferred by any party without the prior written consent of the other party; provided, that any party may assign this Agreement without the prior written consent of the other, to any successor of such first party (by way of merger,
acquisition, reorganization or similar transaction), or purchaser of all or a substantial part of the assets of the business to which this Agreement pertains and provided, further that USNY may assign this Agreement to an Affiliate but only along
with an assignment to such Affiliate of all rights and interest in the Licensed Patent Rights and the Technology Rights. Any permitted assignee of MBI shall succeed to all of the rights and obligations of MBI under this Agreement. The Agreement
shall be binding upon and inure to the benefit of any permitted successor or permitted assignee. 

13.3        Governing Law.   This Agreement shall be governed
by, and construed and interpreted, in accordance with the internal laws of the State of New York without giving effect to any choice of law rules. 

13.4        Arbitration.   Any dispute, controversy, or claim
arising under, out of, or relating to this Agreement (and subsequent amendments thereof), its valid conclusion, binding effect, interpretation, performance, breach or termination, including tort claims, shall be referred to and

  
 12 

 
finally determined by arbitration in accordance with the Rules of Arbitration of the American Arbitration Association under rules for commercial disputes in force at the time when arbitration is
initiated. A sole arbitrator shall be appointed. Such arbitration shall be held in New York. In any legal proceeding (including arbitration) between the parties, the prevailing party will be entitled to recover, in addition to any other relief
awarded or granted, its costs and expenses (including reasonable attorneys’ and expert witness’ fees) incurred in any such proceeding. 

13.5        Notices.   All notices, requests or consents
required or permitted under this Agreement will be made in writing and will be given to the other party by personal delivery, registered or certified mail (with return receipt), overnight air courier (with receipt signature) or facsimile
transmission (with “answerback” confirmation of transmission), sent to such party’s address or telecopy numbers set forth below, or such other addresses or telecopy numbers of which the parties have given notice pursuant to this
Section. Each such notice, request or consent will be deemed effective upon the date of actual receipt, receipt signature or confirmation of transmission, as applicable. 
  

	 	       USNY:
	       The University of the State of New York 

Regents Research Fund 

89 Washington Avenue, Room 2M 

State Education Building 

Albany, NY 12234 
  

	 	       MBI:
	         Marrone Bio Innovations, Inc. 

2121 Second Street, Ste. B-107 

Davis, California 95618 

Attn: President 

Fax: 530-750-2808 

13.6        Indemnity.   MBI shall, at its expense, defend,
indemnify and hold harmless USNY, its directors, officers, managers, employees, representatives, Affiliates and agents (the “Indemnified Parties”) against any third party claim, suit or proceeding (“Claim”) brought against USNY
or its Affiliates and arising out of a breach of any representation or warranty made by MBI in this Agreement or arising out of any allegation of damages resulting from any Licensed Product offered directly or indirectly by MBI, including without
limitation any allegation that such a product or service is defective or has caused damage to person or property, to the extent such Claim arises solely from the actions or inactions of MBI or its Sublicensees; provided that (a) MBI is
notified promptly of any claims brought against an Indemnified Party of which such Indemnified Party has notice, (b) MBI has the sole right to control and defend or settle any litigation within the scope of this indemnity, and (c) the
Indemnified Parties reasonably cooperate in the defense of any claims. 

13.7        No Consequential Damages. SUBJECT TO SECTION 13.6 AND EXCEPT
FOR CLAIMS ARISING OUT OF BREACH OF ARTICLE 10 OR SECTION 13.6, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY.

  
 13 

 13.8        Force
Majeure.   Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment obligations) on account of failure of performance by the defaulting party if the failure is occasioned
by war, strike, fire, Act of God, earthquake, flood, lockout, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence or
intentional conduct or misconduct of the nonperforming party. 

13.9        Severability.   In the event that any provisions
of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. The parties shall in good faith negotiate a substitute
clause for any provision declared invalid or unenforceable, which shall most nearly approximate the intent of the parties in entering this Agreement. 

13.10        Counterparts; Facsimile Signatures.   This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed and delivered by facsimile and upon such
delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 

13.11        Headings.   The headings of the several sections
are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

13.12        Waiver.   Failure by either party hereto to
exercise or enforce any rights conferred upon it by this Agreement will not be deemed to be a waiver of any such rights or operate so as to bar the exercise or enforcement thereof or of any other rights at any subsequent time or times. 

13.13        Status of the Parties.   Nothing in this
Agreement will be construed as to constitute a partnership or joint venture between the parties or authorize either to represent the other party or contract any liability on behalf of the other party. 

13.14        Joint Press Release; Publicity.   Upon execution
of this Agreement or as soon as practicable thereafter, the parties will issue a joint press release, the text of which will be mutually acceptable to the parties. In addition, from time to time during the term hereof, MBI may issue press releases
and other forms of publicity referring to the Licensed Products and USNY’s role with respect thereto, such to be subject to the consent of USNY (such consent not to be unreasonably withheld or delayed). 

[Signature Page Follows] 

  
 14 

 [Signature Page to License Agreement] 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the Effective Date. 

 

									
	 THE UNIVERSITY OF THE

STATE OF NEW YORK
	 		 	 MARRONE BIO INNOVATIONS, INC.

					
	 By:
	 	 /s/ David M. Steiner
	 		 	 By: 
	 	 /s/ Pamela G. Marrone

	 Name:
	 	 David M. Steiner
	 		 		 	 Name: Pamela G. Marrone

	 Title:
	 	 President
	 		 		 	 Title: CEO

  
 15 

 Exhibit A 

Patents 
 Molloy, D. P.
2001. A Method for Controlling Dreissena Species. United States Patent and Trademark Office, U. S. Department of Commerce. Patent No. 6,194,194. (Filed December 17, 1997 & issued February 27, 2001.) 4 pp. 

Molloy, D. P. 2004. A Method for Controlling Dreissena Species. Canadian Intellectual Property Office, Industry Canada. Patent
No. 2,225,436. (Filed December 22, 1997 & issued December 21, 2004.) 13 pp. 

  
 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]